Drug reference
linagliptin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Peptide analogues)
Mechanism of action
Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity which is inactivated by DPP-4 enzyme. Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells
Common side effects
- Nasopharyngitis
- Cough
- Weight gain
- Hypertriglyceridemia
- Hyperlipidemia
Related conditions
Frequently asked questions
What drug class is linagliptin?
linagliptin belongs to: Endocrine.
How does linagliptin work?
Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity which is inactivated by DPP-4 enzyme. Incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells
What are the common side effects of linagliptin?
Nasopharyngitis, Cough, Weight gain, Hypertriglyceridemia, Hyperlipidemia
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.